<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02793908</url>
  </required_header>
  <id_info>
    <org_study_id>UMagnaGraecia</org_study_id>
    <nct_id>NCT02793908</nct_id>
  </id_info>
  <brief_title>Subcutaneous Progesterone Supplementation in Patients With Endometriosis</brief_title>
  <acronym>PleyrisEndom</acronym>
  <official_title>The Role of the Subcutaneous Progesterone in Luteal Phase Supplementation in Patients With Endometriosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Magna Graecia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Magna Graecia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study protocol will be to compare the efficacy of subcutaneous progesterone
      (25 mg / day; Pleyris, IBSA Institut Biochimique SA) with vaginal progesterone (90 mg / day;
      Crinone, Merck Serono) administered during the luteal phase in term of pelvic pain reduction
      in patients with grade I-II endometriosis and / or endometrioma &lt;4 cm subjected to time
      intercourses or COS/IUI cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with grade I-II endometriosis and / or endometrioma &lt;4 cm subjected to time
      intercourses or COS/IUI cycles will be subjected to subcutaneous or vaginal progesterone for
      their luteal phase supplementation in time intercourses or IUI cycles.

      The aim of the study protocol will be to compare the efficacy of subcutaneous progesterone
      (25 mg / day; Pleyris, IBSA Institut Biochimique SA) with vaginal progesterone (90 mg / day;
      Crinone, Merck Serono) administered during the luteal phase in term of pelvic pain reduction
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delta VAS pain</measure>
    <time_frame>7 days after the end of the menstrual period subsequent to the luteal supplementation</time_frame>
    <description>Patients will be asked to score their menstrual pain using a VAS scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic use</measure>
    <time_frame>7 days after the end of the menstrual period subsequent to the luteal supplementation</time_frame>
    <description>Patients will be asked how many vials of analgesics they needed during their menstrual period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>30 days after the end of the menstrual period subsequent to the luteal supplementation</time_frame>
    <description>The percentage of pregnancies achieved in both arms will be assessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Pleyris</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous progesterone will be administered 25 mg a day from the day following the ovulation for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crinone8</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaginal progesterone will be administered 90 mg a day from the day following the ovulation for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pleyris</intervention_name>
    <description>Luteal phase will be supplemented starting by the ovulation day for 14 days</description>
    <arm_group_label>Pleyris</arm_group_label>
    <other_name>Subcutaneous progesterone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crinone8</intervention_name>
    <description>Luteal phase will be supplemented starting by the ovulation day for 14 days</description>
    <arm_group_label>Crinone8</arm_group_label>
    <other_name>vaginal progesterone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Laparoscopic or ultrasonographic diagnosis of endometriosis grade I-II and / or
             endometrioma &lt;4 cm;

          -  Menstrual VAS score&gt; 5 cm before the last menstrual period with progesterone treatment

          -  Infertility for at least 1 year

          -  Body Mass Index 19 to 30 kg / m2

          -  Basal FSH serum &lt;15 IU / ml

          -  Normal levels of serum prolactin

          -  Normal uterine cavity and fallopian patency

        Exclusion Criteria:

          -  Previous ovarian surgery

          -  Endocrine disorders (eg polycystic ovary syndrome, thyroid disease,
             hyperprolactinemia, hypogonadotropic hypogonadism)

          -  Reduced ovarian reserve (basal levels of FSH&gt; 15 IU / mL)

          -  Acute or chronic infectious state

          -  Chronic drug intake, alcohol, or drugs that affect cognitive functions, alertness and
             / or mood

          -  Psychiatric disorders

          -  Kidney or liver diseases

          -  Male factor infertility
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fulvio Zullo</last_name>
    <role>Study Director</role>
    <affiliation>Magna Graecia University of Catanzaro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberta Venturella</last_name>
    <role>Principal Investigator</role>
    <affiliation>Magna Graecia University of Catanzaro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fulvio Zullo, MD, PhD</last_name>
    <phone>337947003</phone>
    <email>zullo@unicz.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Magna Graecia University - Azienda Ospedaliera Pugliese Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fulvio Zullo, MD, PhD</last_name>
      <phone>39337947003</phone>
      <email>zullo@unicz.it</email>
    </contact>
    <investigator>
      <last_name>Roberta Venturella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Magna Graecia</investigator_affiliation>
    <investigator_full_name>Fulvio Zullo</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <keyword>Endometriosis</keyword>
  <keyword>Subcutaneous progesterone</keyword>
  <keyword>luteal phase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be published at the end of the study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

